Ownership history in Frazier Life Sciences Management, L.P. · 6 quarters on record
This page tracks every 13F SEC filing in which Frazier Life Sciences Management, L.P. reported a position in ULTRAGENYX PHARMACEUTICAL IN (RARE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | UNCHANGED | 983,715 | — | 0% | 0.89% | $29.6M | $30.08 |
| 2025 Q2 | ADDED | 983,715 | +325,000 | +49.3% | 1.43% | $35.8M | $36.36 |
| 2025 Q1 | UNCHANGED | 658,715 | — | 0% | 1.09% | $23.9M | $36.21 |
| 2024 Q4 | ADDED | 658,715 | +25,000 | +3.9% | 1.15% | $27.7M | $42.07 |
| 2024 Q3 | ADDED | 633,715 | +208,715 | +49.1% | 1.41% | $35.2M | $55.55 |
| 2024 Q2 | INITIATED | 425,000 | — | — | 0.82% | $17.5M | — |
As of 2025 Q4 — sorted by position size